Alimera Sciences, Inc. (NASDAQ:ALIM)‘s stock had its “buy” rating restated by research analysts at Cowen and Company in a research report issued to clients and investors on Thursday.

The analysts wrote, “Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance.””

ALIM has been the topic of several other research reports. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Tuesday, July 11th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Alimera Sciences has an average rating of “Hold” and an average price target of $3.38.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analyst estimates of $10.20 million. During the same quarter last year, the company posted ($0.17) EPS. Alimera Sciences’s quarterly revenue was up 8.3% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/alimera-sciences-inc-alim-earns-buy-rating-from-cowen-and-company.html.

A number of hedge funds have recently made changes to their positions in ALIM. JW Asset Management LLC lifted its holdings in Alimera Sciences by 15.6% in the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 130,000 shares in the last quarter. KCG Holdings Inc. lifted its holdings in Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 43,977 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 35,200 shares in the last quarter. Institutional investors own 37.20% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.